Skip to main content

and
  1. Article

    Testing the feasibility of operationalizing a prospective, randomized trial with remote cardiac safety EKG monitoring during a pandemic

    The coronavirus SARS-CoV-2 is highly contagious. Hydroxychloroquine (HCQ) has in vitro activity against SARS-CoV-2. The FDA authorized emergency use of HCQ against COVID-19. HCQ may have dose-related cardiotox...

    Hans H. Liu, Michael D. Ezekowitz in Journal of Interventional Cardiac Electrop… (2022)

  2. Article

    Open Access

    The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic

    The World Health Organization declared the outbreak of SARS-CoV-2 a pandemic on February 11, 2020. This organism causes COVID-19 disease and the rapid rise in cases and geographic spread strained healthcare sy...

    Hans H. Liu, Michael D. Ezekowitz, Michele Columbo, Oneib Khan, Jack Martin in Trials (2021)

  3. Article

    Open Access

    Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry

    Anticoagulation is highly effective for the prevention of stroke in patients with atrial fibrillation (AF) but it is dependent on patients continuing therapy. While studies have demonstrated suboptimal therape...

    Larry R. Jackson II, Sunghee Kim, Peter Shrader in Journal of Thrombosis and Thrombolysis (2018)

  4. Article

    Erratum to: A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers

    Michael D. Ezekowitz, Kenneth A. Ellenbogen in Journal of Interventional Cardiac Electrop… (2015)

  5. Article

    Open Access

    A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers

    Dronedarone is a benzofuran derivative with a pharmacological profile similar to amiodarone but has a more rapid onset of action and a much shorter half-life (13–19 h). Our goal was to evaluate the efficacy of...

    Michael D. Ezekowitz, Kenneth A. Ellenbogen in Journal of Interventional Cardiac Electrop… (2015)

  6. No Access

    Article

    Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants—translating clinical trial data into practice

    Anticoagulation for stroke prevention in atrial fibrillation (AF) is effective. Pivotal trials RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE-AF TIMI 48 tested novel agents against warfarin (W). In RE-LY, an open-lab...

    Michael D. Ezekowitz, Judy Spahr in Journal of Interventional Cardiac Electrop… (2014)

  7. No Access

    Article

    A randomized trial of budiodarone in paroxysmal atrial fibrillation

    The aim of this study was to investigate the preliminary safety and efficacy of three doses of budiodarone in patients with paroxysmal atrial fibrillation.

    Michael D. Ezekowitz, Rangadham Nagarakanti in Journal of Interventional Cardiac Electrop… (2012)

  8. No Access

    Article

    2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design

    This is a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation, developed in partnership with the European Heart Rhythm Association (EHRA), a registered ...

    Hugh Calkins, Karl Heinz Kuck in Journal of Interventional Cardiac Electrop… (2012)

  9. No Access

    Article

    Dabigatran in atrial fibrillation: pharmacology and clinical trials

    The central pharmacologic approach to stroke prevention in atrial fibrillation has recently changed with the approval of dabigatran by the US Food and Drug Administration (FDA). Dabigatran is an oral anticoagu...

    Michael D. Ezekowitz, Rangadham Nagarakanti in Journal of Interventional Cardiac Electrop… (2011)

  10. No Access

    Article

    New developments in anticoagulation for atrial fibrillation

    The incidence of stroke in patients with atrial fibrillation (AF) is five times greater than that in age-matched controls. Warfarin reduces this incidence by two thirds and is the most effective agent for this...

    M. Haris U. Usman, Lawrence A. Notaro in Current Treatment Options in Cardiovascula… (2008)

  11. No Access

    Article

    Detection of deep venous thrombosis by DMP 444, a platelet IIb/IIIa antagonist: A preliminary report

    We report a method for detection of deep venous thrombosis with a technetium 99m-labeled peptide (DMP 444). The N-methyl-arginine-glycine-aspartic acid sequence on DMP 444 binds the glycoprotein IIb/IIIa recep...

    Jeffrey A. Klem, Julie V. Schaffer, Paul D. Crane in Journal of Nuclear Cardiology (2000)

  12. No Access

    Article

    Anticoagulation Therapy for Atrial Fibrillation and Coronary Disease

    Michael D. Ezekowitz in Journal of Thrombosis and Thrombolysis (2000)

  13. No Access

    Article

    Pharmacological Control of Rate and Maintenance of Sinus Rhythm

    Michael D. Ezekowitz, Rachel Lampert in Journal of Thrombosis and Thrombolysis (1999)

  14. No Access

    Chapter

    The use of Indium-111 Platelet Scintigraphy in Man: Comparisions with in Vitro Tests and in Vivo Platelet Function — A Five — Year Experience

    This paper reports data collected from 540 patients between July 1978 and July 1983. For the first four years, studies were performed at the Hospitals of the University of Oklahoma Health Science Center and th...

    Michael D. Ezekowitz, Edward L. Snyder in Radiolabeled Cellular Blood Elements (1985)